On August 21, TELLGEN released the 2021 semi-annual report. During the reporting period, TELLGEN’s revenue was 303 million yuan, a year-on-year increase of 157.93%; net profit attributable to the parent was 75 million yuan, a year-on-year increase of 968.67%; basic earnings per share were 0.825 yuan per share, a year-on-year increase of 950.52%.

Since its establishment, the company has been focusing on innovative research and development and has built a professional research and development platform. As of the end of the reporting period, the company had 117 R&D personnel, accounting for 16.41% of the total number of the company. During the reporting period, the R&D investment was RMB 32,906,200, accounting for 10.85% of the company’s operating income during the same period, a year-on-year increase of 23.89%. The company has 117 projects under research, covering multiple fields such as autoimmunity, tumor, cardiovascular, infection, hormones, and metabolism.

At the same time, the company continues to explore overseas markets, actively expand overseas distribution channels, and has established a solid cooperative relationship with overseas distributors. HPV, colorectal cancer Septin9 gene methylation, coronavirus and other products in many fields have obtained CE access qualification or listed The WHO emergency use list can be sold directly in the European Economic Area and WHO member states. Establishing a stable and good cooperative relationship with overseas distributors will lay the foundation for the company to fully expand overseas markets in the future. As of the end of the reporting period, the company has carried out sales in Europe, the Middle East, Southeast Asia and other countries and regions. During the reporting period, it achieved overseas operating income of RMB 22,372,200, a year-on-year increase of 11,261.16%.

During the reporting period, the company completed the installation (including sales) of 462 instruments of various types. Although the successful installation of these instruments has increased the company’s sales expenses, it will bring more reagent sales revenue in the future, which will continue to increase the company’s product revenue. The company has also established a fully functional marketing department and a sales team with a reasonable staff structure. It has a technical support service team of more than 170 people, and provides technical training and support services to dealers and customers, which further enhances the company's sales and service capabilities.